Company / Net Income
Vistagen Therapeutics, Inc. Net Income History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$47.8M
FY2023
5-year range
-$47.8M / -$10.3M
FY2019-FY2023
Trend
-166.3%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 8 years, ranging from -$48M in FY2023 to -$230,900 in FY2012.
Based on SEC 10-K filings.
-$48M in FY2023.
Declined from -$21M to -$48M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, net income decreased 166.3% year-over-year.
- Peak net income was recorded in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | -$47.8M | -166.3% |
| FY2022 | -$17.9M | +13.7% |
| FY2021 | -$20.8M | -102.6% |
| FY2018 | -$10.3M | +78.3% |
| FY2017 | -$47.2M | -10.5% |
| FY2014 | -$42.7M | -18399.5% |
| FY2012 | -$230.9K | +0.0% |
| FY2011 | -$230.9K | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026